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year mortality after primary angioplasty for STEMI. Therefore, the use of statins after
STEMI is highly recommended.
9:15 a.m.
833-4 Undertreatment of Low Serum High-Density Lipoprotein 
Cholesterol in Patients With Acute Myocardial Infarction
Anjli Maroo, W. H. Wilson Tang, Byron Hoogwerf, Stephen G. Ellis, Cleveland Clinic 
Foundation, Cleveland, OH
Background: The prevelance of low serum high-density lipoprotein cholesterol (HDL-C)
in patients with acute myocardial infarction (AMI) is understudied. We examined contem-
porary patients hospitalized for AMI in order to determine the prevelance, clinical charac-
teristics, and treatment patterns of those with low HDL-C (</= 40 mg/dL).
Methods: We reviewed 346 consecutive patients who presented with AMI and under-
went urgent revascularization with percutaneous coronary intervention between 1/2000-
12/2001. We excluded patients who had lipid panels drawn > 24 hours after presentation
or who were cachectic (total cholesterol <100 mg/dL) (n=81). We compared clinical and
laboratory data between patients with low HDL-C and HDL-C > 40 mg/dL by univariate
analysis.
Results: In our cohort of 265 patients (mean age 61+/-14 years, 65% male, 20% dia-
betic, mean left ventricular ejection fraction 44+/-12%), 147 patients (55%) had low HDL-
C. Compared to those with normal HDL-C, those with low HDL-C were younger, were
more likely to be male, had lower systolic blood pressure, were more likely to be actively
smoking, and had higher serum triglycerides (177 vs 110 mg/dL) (p</=0.01). There were
no statistically significant differences in the number of diabetic patients or in mean LDL-C
levels (105 vs 106 mg/dL) in either group. Overall, 49% of the entire cohort, and 29% of
those with low HDL-C, had LDL-C levels </= 100 mg/dL. Only 7 patients (6%) in the low
HDL-C group were discharged on niacin or fibrate preparations, even though 86 patients
(59%) had no contraindications to pharmacotherapy. In contrast, 90% of the entire cohort
(85% of the low HDL-C group) were discharged with statins.
Conclusions: Low HDL-C is highly prevalent (55%) in contemporary patients with AMI,
many of whom have LDL-C levels below recommended targets. Although aggressive
LCL-C lowering attenuates some of the adverse effects of low HDL-C, secondary preven-
tion models that focus on targeting LDL-C alone do not adequately address current pat-
terns of dyslipidemia. The opportunity for inclusion of HDL-C raising therapies prior to
discharge in post-MI patients is clear.
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833-5 Markers of Inflammation Predict Mortality and Are 
Reduced by Pexelizumab in Patients With Acute 
Myocardial Infarction: Insights From the Complement 
Inhibition in Myocardial Infarction Treated With 
Angioplasty (COMMA) Trial
Pierre Theroux, Paul W. Armstrong, Kenneth W. Mahaffey, Judith S. Hochman, Scott 
Rollins, Kevin J. Malloy, Thomas Parish, Jose C. Nicolau, Joel Lavoie, Christopher B. 
Granger, Montreal Heart Institute, Montreal, PQ, Canada
Background: In the COMMA trial, inhibition of the complement protein C5 with pexeli-
zumab (Pex) paradoxically reduced mortality without influencing infarct size (Circulation
2003;108). We examined plasma markers to investigate the role of inflammation and the
impact of treatment.
Methods: 350 patients in the Pex bolus and infusion and placebo groups were studied at
baseline before Pex and PCI, at the end of infusion (24 hours), and 48 hours later. Levels
of hsCRP were assessed by nephelometry, and IL-6 and TNFα by ELISA.
Results: All markers increased from baseline through 72 h (p<0.001). IL-6 levels peaked
at 24 h, hsCRP and TNFα at 72 h. Older age and elevated CK-MB (AUC) were associ-
ated with higher IL-6 and hsCRP.
HsCRP was lower in the Pex group at 24 h (p=0.02). Levels of IL-6 and hsCRP were sig-
nificantly reduced in Pex patients > 65 years at 24 h and 72 h; hsCRP in those with CK-
MB > median was similarly reduced. Mortality at 90 days was strongly related to baseline
levels of IL-6 (OR per increasing quartile: 3.2, 95% CI: 1.7-5.9), hsCRP (1.6, 1.1-2.5),
and TNFα (1.4, 0.9-2.1). 
Conclusion: In the MI population undergoing primary PCI, inflammation intensity corre-
lated with older age and higher CK-MB, and basal values predicted mortality. Pex 
appeared to reduce hsCRP during drug infusion, and sustained a reduction of hsCRP 
and IL-6 in high-risk patients. The novel findings support both a role for inflammation and 
the complement in MI, and a potential explanation for the treatment effect of C5 inhibition 
with pexelizumab.
9:45 a.m.
833-6 An Updated Meta-Analysis of the Effect of Glucose-
Insulin-Potassium on Survival in Acute Myocardial 
Infarction: Impact of Reperfusion Therapy
Ramesh M. Gowda, David L. Brown, Beth Israel Medical Center, New York, NY
Background: Glucose-insulin-potassium (GIK) has been proposed as adjuvant therapy
in acute myocardial infarction (AMI) because of its ability to induce multiple favorable
metabolic alterations in the cardiac myocyte. However, randomized controlled trials per-
formed over the last 4 decades have yielded conflicting results regarding the impact of
GIK on mortality in AMI. We performed an updated meta-analysis to investigate the effect
of GIK on mortality in AMI. Methods: A comprehensive MEDLINE search revealed 13
randomized controlled trials of GIK treatment in AMI. The odds ratios of the individual tri-
als were pooled using a random effects model. Separate meta-analyses were performed
of the 9 studies in which no reperfusion therapy was provided and the 4 studies in which
GIK was administered in addition to reperfusion therapy. Results: Of the 4149 patients
randomized, 2145 received GIK while 2004 were in the control groups. Mortality was
reduced from 13% (257/2004) in the control group to 11% (234/2145) in the GIK-treated
patients (Odds Ratio (OR), 0.78; 95% confidence interval (CI), 0.58 to 1.05; P=0.106). In
the trials performed without reperfusion therapy, the mortality was reduced from 20.5%
(192/934) in the control group to 16.6% (149/897) in the GIK-treated group (OR, 0.77;
95% CI, 0.60 to 0.98; P=0.034). In the trials with reperfusion therapy, there was a slight
increase in mortality from 6.0% (65 /1070) in the control group to 6.8% (85/1248) in the
GIK-treated patients (OR, 0.97, 95% CI, 0.46 to 2.0; P=0.945). Conclusion: There
appears to be a trend toward a reduction in mortality by GIK in AMI. However, the benefit
of GIK is restricted to patients who do not receive reperfusion therapy. Patients who
receive reperfusion therapy do not benefit from GIK. GIK should be considered for AMI
patients who are not eligible for reperfusion therapy.
Table of Contents
² 1 Median Concentrations
² 1 Baseline
² 1 Age > 65 yrs
² 1 CK-MB > median
Median Concentrations
Baseline 24 h 72 h
All patients Pl Pex Pl Pex Pl Pex
IL-6 (pg/mL) 12.2 12.9 63.8 50.6 35.6 33.5
HsCRP (mg/L) 3.3 2.8 25.1 17.1* 41.5 35.9
TNFα (pg/mL) 0.88 0.82 1.16 1.44 1.57 1.65
Age > 65 yrs
IL-6 16.7 14.8 88.2 56.1** 64.4 41.7*
HsCRP 3.5 3.7 31.7 17.9* 84.5 39.4**
CK-MB > median
HsCRP 3.5 2.7 31.9 19.1** 74.4 45.1*
Pex vs placebo, * p<0.05, **p<0.01
